| abstract |
The present disclosure relates to an anti-CD79B antibody, the antigen-binding fragment thereof, and the pharmaceutical use thereof. Further, the present disclosure relates to a chimeric antibody, a humanized antibody including the CDR region of the anti-CD79B antibody, and a pharmaceutical composition comprising the human anti-CD79B antibody or antigen-binding fragment thereof, and use thereof as an anticancer drug. In particular, the present disclosure relates to the use of the humanized anti-CD79B antibody in the manufacture of a medicament for the treatment of lymphomas, such as DLBCL. |